Why the ResMed Inc. share price just hit another record high

The share price of sleep treatment specialist ResMed Inc. (ASX:RMD) hit a record high of $16.52 in Tuesday trade before retreating to close up 0.2% to $16.36.

Shareholders of the Australian listed scrip have seen their shares appreciate 48% over the last 12 months, comfortably outperforming the broader market’s loss of 2%. The impressive rise has been a result of strong earnings growth from the expansion of the company’s product portfolio with new masks and ongoing upgrades to its digital health solutions driving revenue growth. Effective cost control has also boosted the bottom line.

Furthermore, the falling Australian dollar has lifted the share price of the Australian listed scrip as it represents a 1/10th ownership interest in the NYSE scrip where the company has its primary listing.

Focus will now shift towards ResMed’s Q2 2019 earnings report that is scheduled for release on Friday morning. The current earnings per share consensus estimate for the quarter is 92 US cents per The Wall Street Journal.

ResMed and other healthcare stocks such as CSL Limited (ASX:CSL) and Cochlear Limited (ASX:COH) have some of the best prospects for solid long-term growth at the larger end of the Australian market that is heavily weighted towards the large banks and other mature businesses.

JUST RELEASED: Our Top 3 Dividend Bets for 2019

NEW! The Motley Fool’s team of crack analysts has just released a timely report revealing the names and codes of their top 3 dividend share recommendations for 2019. Be among the first investors to get access—FREE, for a strictly limited time. You’ll discover the names of 3 hefty dividend paying companies with what our analysts consider to be solid growth prospects for the year ahead…

The first two currently offer fat, fully franked yields and the third is a surprising REIT offering you the chance to become a landlord with none of the hassle! If you’re looking for hot new ideas, look no further. But you do need to hurry. Snap up your free copy now, before supplies run out!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our top 3 dividend share recommendations right away.

Motley Fool contributor Tim Katavic owns shares in ResMed Inc. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!